Literature DB >> 19264600

Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Congrong Miao1, Gertrud U Radu1, Hayat Caidi1, Ralph A Tripp2, Larry J Anderson1, Lia M Haynes1.   

Abstract

Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-gamma) production in the lungs of RSV-infected mice. Its F(ab')(2) component only mediates decreased leukocyte trafficking and IFN-gamma production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19264600      PMCID： PMC2887562          DOI： 10.1099/vir.0.009308-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  22 in total

Review 1.  RSV-induced immunopathology: dynamic interplay between the virus and host immune response.

Authors:  Steven M Varga; Thomas J Braciale
Journal:  Virology       Date:  2002-04-10       Impact factor: 3.616

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 4.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

5.  Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.

Authors:  Jennifer L Harcourt; Ruth A Karron; Ralph A Tripp
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

Review 6.  Bronchiolitis in infants.

Authors:  H B Panitch
Journal:  Curr Opin Pediatr       Date:  2001-06       Impact factor: 2.856

7.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 125I or 111In.

Authors:  B A Brown; R D Comeau; P L Jones; F A Liberatore; W P Neacy; H Sands; B M Gallagher
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

9.  CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.

Authors:  Jennifer L Harcourt; Michael P Brown; Larry J Anderson; Ralph A Tripp
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

10.  Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.

Authors:  S Corbeil; C Seguin; M Trudel
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641
View more
  36 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 2.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

3.  Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Authors:  S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Authors:  Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

5.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

Review 6.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

7.  An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Sean O Todd; Tatiana Chirkova; Thomas R Barnum; Kelsey A Gaston; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  Virology       Date:  2015-05-15       Impact factor: 3.616

8.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.